Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole.
1. The metabolism of the radiosensitizing 2-nitroimidazole, misonidazole, has been investigated in mice, rats, baboons, human volunteers, and in patients receiving radiotherapy for advanced malignant disease. 2. Plasma levels of unchanged drug and its desmethylated metabolite have been measured, and in humans there is good correlation of peak plasma concn. with drug dose. All drug-related material in plasma was accounted for as unchanged misonidazole or its desmethylated metabolite, both compounds being radiosensitizers in vitro. 3. Extensive faecal excretion of material not containing any nitro group occurred in mice, rats, and baboons dosed with radiolabelled drug. 4. Renal excretion is the preferred route of elimination in man, baboon and mouse. Nitroimidazole metabolites accounting for over half the urinary excretion in all species were identified. 5. The compound penetrates solid murine tumours in concentrations sufficient to achieve radiosensitization.
D000818:Animals; D002849:Chromatography, Gas; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D005260:Female; D000882:Haplorhini; D006801:Humans; D007700:Kinetics; D008297:Male; D013058:Mass Spectrometry; D051379:Mice; D009593:Nitroimidazoles / Q000378:metabolism*; D010215:Papio; D011838:Radiation-Sensitizing Agents / Q000378:metabolism*; D051381:Rats
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents